Cargando…

Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression

Neuroimmune-triggered neuroinflammation of the central nervous system is emerging as an important aetiopathogenic factor for multiple neurological disorders, including depression, dementia, Alzheimer’s disease, multiple sclerosis and others. Tryptophan metabolism via the kynurenic pathway, which is...

Descripción completa

Detalles Bibliográficos
Autores principales: Savonije, Karl, Meek, Autumn, Weaver, Donald F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296628/
https://www.ncbi.nlm.nih.gov/pubmed/37371332
http://dx.doi.org/10.3390/brainsci13060852
_version_ 1785063694535753728
author Savonije, Karl
Meek, Autumn
Weaver, Donald F.
author_facet Savonije, Karl
Meek, Autumn
Weaver, Donald F.
author_sort Savonije, Karl
collection PubMed
description Neuroimmune-triggered neuroinflammation of the central nervous system is emerging as an important aetiopathogenic factor for multiple neurological disorders, including depression, dementia, Alzheimer’s disease, multiple sclerosis and others. Tryptophan metabolism via the kynurenic pathway, which is initiated by the indoleamine-2,3-dioxygenase (IDO-1) enzyme, is a key regulator of the neuroimmune system and its associated neuroinflammatory effects. As discussed in this review, targeting the production of immunopathic and potentially neurotoxic kynurenine metabolites by inhibitory downregulation of IDO-1 may prove a viable target against inflammation-induced neurological conditions, particularly depression and dementia.
format Online
Article
Text
id pubmed-10296628
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102966282023-06-28 Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression Savonije, Karl Meek, Autumn Weaver, Donald F. Brain Sci Review Neuroimmune-triggered neuroinflammation of the central nervous system is emerging as an important aetiopathogenic factor for multiple neurological disorders, including depression, dementia, Alzheimer’s disease, multiple sclerosis and others. Tryptophan metabolism via the kynurenic pathway, which is initiated by the indoleamine-2,3-dioxygenase (IDO-1) enzyme, is a key regulator of the neuroimmune system and its associated neuroinflammatory effects. As discussed in this review, targeting the production of immunopathic and potentially neurotoxic kynurenine metabolites by inhibitory downregulation of IDO-1 may prove a viable target against inflammation-induced neurological conditions, particularly depression and dementia. MDPI 2023-05-24 /pmc/articles/PMC10296628/ /pubmed/37371332 http://dx.doi.org/10.3390/brainsci13060852 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Savonije, Karl
Meek, Autumn
Weaver, Donald F.
Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
title Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
title_full Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
title_fullStr Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
title_full_unstemmed Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
title_short Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
title_sort indoleamine 2,3-dioxygenase as a therapeutic target for alzheimer’s disease and geriatric depression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296628/
https://www.ncbi.nlm.nih.gov/pubmed/37371332
http://dx.doi.org/10.3390/brainsci13060852
work_keys_str_mv AT savonijekarl indoleamine23dioxygenaseasatherapeutictargetforalzheimersdiseaseandgeriatricdepression
AT meekautumn indoleamine23dioxygenaseasatherapeutictargetforalzheimersdiseaseandgeriatricdepression
AT weaverdonaldf indoleamine23dioxygenaseasatherapeutictargetforalzheimersdiseaseandgeriatricdepression